🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Ireland / NCT07476807
Enrolling by invitation Not applicable

Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study

NCT07476807 · tracked via the Priya Life Science Ireland tracker
Sponsor
Sligo General Hospital
Phase
Not applicable
Started
2026-04-01
Last updated
2026-04-28

Condition(s) studied

RashSystemic TreatmentsTele-assessment

Investigational drug(s) / intervention(s)

telem healthassessment

telem healthassessment: SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders

Study summary

This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria:Participants must meet all of the following criteria: * Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT). * New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT. * Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria. * Clinically stable condition not requiring urgent in-person evaluation. * Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations. Exclusion Criteria: Participants will be excluded if any of the following criteria apply: * Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria. * Clinical status requiring urgent or immediate face-to-face medical assessment. * Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects. * Inability to access or effectively use the required telemedicine technology.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sligo university Hospital Sligo Sligo

More Sligo General Hospital trials in Ireland

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07476807 on ClinicalTrials.gov ↗ ← All trials in Ireland